25.2 C
Vientiane
Wednesday, September 17, 2025
spot_img
Home Blog Page 27

New Data, iCARE Study: Hailie® Smartinhaler® Powers Unprecedented Medication Adherence in Patients with COPD and Asthma

Highlights:

  • Up to 235% increase in real-world adherence compared to published norms (20–40%), across ~850 chronic obstructive pulmonary disease (COPD) and asthma patients.
  • >60% patients achieved an average two-week baseline adherence with ~4 in 10 patients reaching the critical threshold of >80% adherence, a level associated with 50% fewer exacerbations and lower hospitalisations.
  • Sustained engagement of 12+ months with 54% persistence even in high-risk, elderly patients, far above typical digital health benchmarks (30–45%).
  • Clinically meaningful reductions in admissions, readmissions, and overall care costs, directly aligned with payer and health system value-based care priorities.
  • Clear multi-billion-dollar commercial opportunity, positioning Adherium’s Hailie® Smartinhaler® as a scalable, defensible platform for U.S. and global expansion.

MELBOURNE, Australia, Sept. 15, 2025 /PRNewswire/ — Adherium Limited (ASX: ADR), a global leader in connected respiratory health solutions, has today announced preliminary results from the groundbreaking iCARE study, a real-world study conducted in partnership Intermountain Health, a leading nonprofit US health provider, and CareCentra, an AI-driven prevention-as-a-service remote monitoring platform.

The iCARE study (‘the Study’) has resulted in significant positive clinical outcomes, including record adherence rates and consistent patient engagement for patients with COPD and asthma. The Study included the supply of 4,000 Halie® Smartinhalers®, supporting up to 2,500 COPD and asthma patients across five Intermountain Health facilities over two years.

Adherium Chief Executive Officer, Dawn Bitz, said: “By generating actionable patient data, including biometrics from Adherium’s Smartinhaler technology, the iCARE study demonstrates breakthrough adherence, unprecedented patient persistence, reduced hospitalisations, and significant potential cost savings. This data lays strong foundations for a scalable, value-based care model with global commercial relevance. We are now on track to close one of the largest historical gaps in respiratory management, unlocking value for patients, providers, payers, and investors alike.”

Analysis of the ~850 Intermountain Health patients enrolled in the Study revealed compelling clinical results. Adherence was evaluated in a subset of patients with connected controller inhalers and at least 30 days of inhalation data. Across this group, patients used their inhalers on average nearly two-thirds of the time, far higher than the roughly one-in-five times typically reported in these populations, marking one of the strongest independent, real-world adherence outcomes recorded in chronic respiratory care. Average two-week baseline adherence was 62%, with ~4 in 10 patients reaching the critical threshold of greater than 80% adherence, a level long associated with nearly 50% fewer respiratory attacks.

Separately, analysis of nearly 700 patients demonstrated clinically meaningful improvements across multiple dimensions of respiratory care including reductions in inpatient admissions, 30-day readmissions, average length of stay and lower reliance on rescue medications; resulting in decreases in overall cost of care.

The iCARE study also demonstrated strong persistence (“stickiness”) of the CareCentra remote monitoring platform, with more than half active users staying engaged for over a year, far outpacing expectations typically reported in behaviour -change program. Engagement was the highest in elderly, high-risk patients, including those with depression, proving that technology-enabled support can make a lasting difference even for the hardest to reach patients, and those least likely to adopt or sustain digital health interventions. These patients also represent the highest-cost segment of the healthcare system, requiring the most hospitalisations and readmissions. 

Adherium Chief Executive Officer, Dawn Bitz, said: “These interim results prove that digital health can deliver both measurable patient impact and health system value at scale. By combining innovative connected inhaler technology with CareCentra’s AI-driven behavioural engagement, we are not only improving adherence but also validating a sustainable, value-based care model.

“At the same time, outpatient encounters are increasing, reflecting earlier, proactive interventions that prevent costly crisis-level exacerbations. Together, these shifts demonstrate iCARE’s potential to fundamentally bend the cost curve in respiratory disease management—an outcome highly aligned with payer priorities in both U.S. and Australian markets.”

Intermountain Health Research Director for Respiratory Care Clinical Services, Kim Bennion, said: “For patients living with chronic respiratory disease, what happens between clinic visits often determines whether their condition stabilises or escalates. Through the iCARE program with continuous respiratory monitoring and nudging technology, we are giving our patients the tools and support to stay on therapy, avoid hospitalisations, and maintain a higher quality of life. These early results affirm the power of technology-enabled care to extend our reach beyond the hospital and clinic walls.”

The Study also presents opportunities for deeper analysis by condition type (COPD vs. asthma), patient severity (e.g., prior hospitalisations, GINA or GOLD classifications), environmental and weather-related factors, and socioeconomic influences on participation and outcomes, said Bennion.

A statistically more comprehensive dataset with detailed breakdowns will be released later but these results already serve as a leading indicator of iCARE’s ability to sustain engagement over time, and to deliver enduring value for patients, payers, and health systems.

Commerical Significance

  • Adherium considers these preliminary results to be material under Listing Rule 3.1 because they demonstrate the scalability of the Hailie® platform in a leading U.S. health system, providing clinical validation that supports commercial expansion opportunities and payer engagement.
  • These results are preliminary in nature and further data and analysis will be required before final conclusions can be drawn. Accordingly, while the findings are encouraging, they should not be taken as guarantees of future outcomes.
  • Whilst the Study is currently being delivered in a research framework, these positive results position Adherium for new contracts, expanded sales and reimbursement.
  • The iCARE study is the largest real-world respiratory monitoring care program for chronic obstructive pulmonary disease (COPD) and asthma patients. The Study included the supply of 4,000 Hailie® sensors, supporting up to 2,500 chronic obstructive pulmonary disease (COPD) and asthma patients, across five Intermountain facilities over a two-year period, underscoring both the scale of the program and the commercial adoption of Adherium’s technology.

Background

  • Pressing global challenge: Asthma and COPD affect 40M in the U.S. and over 700M worldwide, with poor adherence the biggest barrier to better outcomes.
  • Closing the adherence gap: Real-world adherence is often just 20–40%. In iCARE, adherence improved by up to 235%.
  • Gold standard achieved: One third of patients-maintained adherence levels of > 80% during the entirety of the study, compared to single-digit rates in earlier studies.
  • Scale and persistence: Nearly 1,000 patients, with two-thirds of doses taken as prescribed and more than 9 in 10 remain active after a year. Results unmatched by other digital health programs.
  • Engaging the hardest to reach: Over half of patients remained engaged for a year, with the strongest persistence among elderly, high-risk patients including those aged 70 to 80.
  • Engine of iCARE: Powered by Adherium’s Hailie® Smartinhaler® technology, which captures use, identifies technique errors, and enables real-time intervention, turning data into action for patients and providers.
  • System-level impact: Early results show fewer hospital admissions, fewer readmissions, shorter stays, and less reliance on rescue medications, translating to better patient lives and lower system costs.
  • Economic relevance: COPD drives over $31B in U.S. healthcare costs annually. Adherium’s technology directly addresses payer and provider priorities in value-based care.
  • Investor significance: Adherium is the data engine behind iCARE and owns the insight pipeline, positioning the company for a multi-billion-dollar global opportunity.

Forward-Looking Statements: This announcement may contain forward-looking statements. These statements are based on current expectations, assumptions and uncertainties, and actual results may differ materially from those expressed or implied. Adherium undertakes no obligation to update or revise forward-looking statements except as required by law.

Learn more at adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries
Adherium Limited
investors@adherium.com

About Adherium (ASX:ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium’s Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium’s own broad range of sensors connected to respiratory medications. Adherium’s Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at adherium.com

About CareCentra, Inc

CareCentra, Inc. is a patient behavior-shaping company based in the U.S. that enables value-based care through an AI-driven, prevention-as-a-service remote monitoring platform. The CareCentra platform for continuous connected care

leverages advanced decision science, nudge theory, behavior science and personal technologies to enable remote monitoring and coordinate care for patients across the entire spectrum of chronic and acute conditions. CareCentra’s AI-driven platform was proven to better patient outcomes and lower healthcare costs in

Randomized Clinical Trials and is now used at several U.S. health systems to reduce admission/readmission while increasing patient engagement and improving care plan adherence.

About Intermountain Health

Headquartered in Utah with locations in six Western states, Intermountain Health is a nonprofit health system comprising 34 hospitals, approximately 385 clinics, and medical groups with some 3,900 employed physicians and advanced care providers, as well as a health plan division called SelectHealth—serving more than one million members. Helping people live the healthiest lives possible, Intermountain is committed to improving community health and is widely recognized for transforming healthcare by using evidence-based best practices to deliver high-quality outcomes at sustainable costs.

WePlay Teams Up with CHIBI MARUKO-CHAN to Celebrate Its Fourth Anniversary!

TOKYO, Sept. 15, 2025 /PRNewswire/ — The highly popular social entertainment app WePlay announced today that, to express gratitude for users’ longstanding support, it has invited the iconic Japanese anime IP “CHIBI MARUKO-CHAN” to join its anniversary celebration lineup.

WePlay Teams Up with CHIBI MARUKO-CHAN to Celebrate Its Fourth Anniversary!
WePlay Teams Up with CHIBI MARUKO-CHAN to Celebrate Its Fourth Anniversary!

Maruko Joins WePlay for a Surprise Party

From 12:00 PM on September 16 to 12:00 AM on September 26, Maruko will appear as a virtual guest for the very first time on WePlay’s voice rooms. She will interact closely with players, sharing cheerful greetings and delightful surprises. Maruko’s signature smile and everyday stories will bring a warm, healing vibe to the WePlay community.

Exclusive Fourth Anniversary Rewards

  • Exclusive Maruko Virtual Gifts: Specially designed collectible items to make your interactions even more meaningful.
  • Exclusive CHIBI MARUKO-CHAN avatar: Use the exclusive avatar to transform into Maruko and join the anniversary celebration;
  • Will’s Birthday Surprise Party: Spend a heartwarming online celebration with Will and CHIBI MARUKO-CHAN.

CHIBI MARUKO-CHAN: A Beloved Cultural Icon

Originally created by Momoko Sakura, CHIBI MARUKO-CHAN is set in Shimizu City, Shizuoka Prefecture (now Shimizu Ward, Shizuoka City), and warmly depicts the everyday life of the Sakura family—especially Maruko, the second daughter and a third-grade elementary school student—as well as her family and friends. The series began serialization in Ribon (SHUEISHA) in 1986 and celebrated its 35th anniversary in 2021.

The television anime adaptation began airing in 1990 and is still broadcast every Sunday at 6 p.m. on the Fuji TV network. The show has also been broadcast in Greater China and many other regions, captivating audiences of all ages around the world and continuing to be beloved for generations.

Four Years of Connection, Same Original Mission

Since launching in Japan four years ago, WePlay has remained committed to creating fun, heartwarming, and diverse social experiences. Through this anniversary celebration, WePlay aims to deliver more surprises and lasting memories while embarking on the next exciting chapter together with its community.

About WePlay

WePlay, a global social entertainment platform under Singapore-based Wejoy, integrates games, entertainment, and social features. With a mission to “Bring joy and friends to young people around the world,” WePlay is committed to co-create an innovative era of gaming and social experiences.

Contactqipeinan@wejoysg.com
Websitehttps://weplayapp.com/

 

MGI Tech Introduces DNBSEQ-T7+: A Next-Generation ‘Data Mining Machine’ for Genomics

SHENZHEN, China, Sept. 15, 2025 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for large-scale genomic research, the T7+ delivers more than 14 Tb/day of data in just 24 hours while offering a smaller footprint, flexible run configurations, and end-to-end automation. Internally dubbed a “data mining machine,” the T7+ redefines high-throughput sequencing by combining daily output with ease of use and multi-omics versatility.


DNBSEQ-T7+

DNBSEQ-T7+
DNBSEQ-T7+

A New Era in High-Throughput Sequencing

The T7+ integrates MGI’s proprietary DNBSEQ™ technology with next-generation fluidics, optics, and bioinformatics, creating a platform that is faster, smarter, and more versatile than ever before. The compact system supports 1–4 flow cells per run, adapts to projects of any scale, and integrates every step—from DNB preparation to bioinformatics analysis—into a fully automated workflow.

Key technical highlights include:

  • Throughput: More than 14 Tb/day (vs. 7 Tb/day on T7)
  • Annual Capacity: Up to 35,000 whole-genome sequencing (WGS)
  • Accuracy: >90% Q40 quality scores, validated in beta testing by leading labs
  • Speed: PE150 reads in under 24 hours
  • Flexibility: Configurable for mid- or large-scale studies
  • Size Efficiency: 1 m²
  • 7-in-1 Integration: Hardware + software architecture eliminates manual preparation steps
  • Scanning Time: 50% reduced by the TDI(Time-Delay Integration) camera.
  • One-Stop Workflow: Built-in automation from DNB preparation to bioinformatics
  • Reduced energy consumption: Over 90% of transport links and certain reagents require no cold chain.

With these capabilities, the T7+ enables researchers to sequence 144 human genomes in a single day, accelerating breakthroughs in cancer genomics, rare disease research, and precision medicine.

From T7 to T7+: Continuing the T Series Legacy

The DNBSEQ-T7, launched in 2018, was a breakthrough in the T Series, setting a new benchmark for high-throughput sequencing by delivering up to 7 terabases (Tb) of data in 24 hours. With over 400 units installed at more than 200 leading institutions worldwide, such as national initiatives, including Thailand’s Genomics Thailand Initiative and Brazil’s largest genomic sequencing project. This milestone redefined sequencing speed and accessibility, cementing the T Series as a cornerstone of genomic innovation.

As sequencing becomes increasingly affordable, researchers are demanding instruments that deliver higher throughput, faster results, and uncompromising accuracy and quality. That’s why MGI developed the T7+, an advanced continuation of the T7 designed to deliver greater speed, scalability, high flexibility, and performance to meet the evolving demands of clinical research, population genomics, and large-scale sequencing projects.

T7 was a breakthrough in specs, while the T7+ breaks new ground in user experience.

Redefining High-Throughput Sequencing

T7+ solves the universal trade-offs researchers face—speed versus capacity, usability versus cost. By integrating 7-in-1 hardware, smartphone-like software, and modular-designed consumables, the T7+ makes sequencing as intuitive as using a smartphone. Its ability to support multi-omics applications—spatial omics, single-cell, proteomics, methylation—in one run enables concurrent data streams for large cohorts.

“The T7+ is more than just a sequencer—it is a bridge between scientific discovery and real-world health outcomes,” added Duncan Yu, President of MGI Tech. “With higher throughput, improved accuracy, and a smaller footprint, the T7+ empowers scientists to ask bigger questions and deliver insights faster. Every genome sequenced has the potential to accelerate rare disease diagnosis, guide precision oncology, and inform public health at scale.”

Early adopters of the T7+ are already deploying it in population-scale studies, where its short-read power, combined with cyclone long-read data, enhances structural variant detection and rare disease analysis. Others are pairing the T7+ with long-read platforms for single-cell studies, opening new opportunities in understanding genetic diversity and cellular complexity.

T7+ is now open to order. International shipments begin in late 2025.

OROJIN™️ Makes Global Debut at BIOHK 2025 to Lead The Future of Preventive Medicine

Breakthrough Chewable Chlorogenic Acid Tablet Designed To Support Immunity, Cellular Vitality and Metabolism.


HONG KONG SAR – Media OutReach Newswire – 15 September 2025 – OROJIN™️, the breakthrough oral chewable tablet system was unveiled at BIOHK 2025, one of the world’s most influential biotechnology gatherings. Signalling the beginning of a new era in preventive medicine, OROJIN™️ was created to redefine the way people approach their health. More than a supplement, OROJIN™️ delivers a daily dose of chlorogenic acid, a powerful antioxidant that supports immunity, cellular vitality, and promotes metabolic harmony. A “Daily Act of Self-Respect”, OROJIN™️ empowers people everywhere to live stronger, healthier, and more fulfilled lives.

OROJIN™️ Makes Global Debut at BIOHK 2025 to Lead The Future of Preventive Medicine

Science That Protects

Developed in collaboration with leading professors and medical pioneers from the Miskawaan Health Group (MHG) and Jiuzhang Biotech, OROJIN™️ is built on advanced research into chlorogenic acid, one of nature’s most potent antioxidant compounds. Extracted from Eucommia leaves using a comprehensive, proprietary system, its researched benefits include:

  • Neutralizing free radicals that damage DNA and accelerate aging. 1
  • Calming chronic inflammation, the root cause of many diseases.2
  • Restoring healthy cell signalling and boosting natural energy transport in the body, leading to beneficial metabolic effects. 3
  • Protecting vital organs, including the heart, liver, gut, and brain. 4
  • Encouraging restful sleep, and supporting memory and focus. 5

A New Standard in Preventive Medicine

With OROJIN™️, science becomes simple, accessible, and actionable in everyday life. “OROJIN™️ is not just another product — it is the beginning of a movement,” said David Boehm, Chairman of OROJIN™️ and Miskawaan Health Group. “This launch represents a mindset shift, encouraging people to take a proactive interest and care in their own health and wellbeing journey. We are delighted to be part of a new and empowered approach to wellness that starts with daily proactive care,” he added.

Global Launch Celebration at BIOHK 2025

The launch celebrations were led by David Boehm, Chairman of OROJIN™️, and Miskawaan Health Group, and Zhang Jie, Founder and Chairman of Jiuzhang Biotech. They included a Ribbon Cutting Ceremony featuring the OROJIN PreventaPanda™️, a beloved symbol of proactive health.

References

  1. Ogawa H, et al. Chem Lett. 2023;52:524-527.
  2. Huang J, et al. Front Pharmacol. 2023 Sep 13:14:1218015.
  3. Meng S, et al. Evid Based Complement Alternat Med. 2013:2013:801457.
  4. Lu H, et al. Compr Rev Food Sci Food Saf. 2020;19:3130-3158.
  5. Saitou K, et al. Nutrients. 2018;10:1337.

Disclaimer: This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.
Hashtag: #OROJIN

The issuer is solely responsible for the content of this announcement.

About OROJIN™️

is the world’s first complete preventive wellness system, built on decades of scientific research and inspired by the belief that prevention is the highest form of care. Designed for global impact, OROJIN™️ empowers individuals everywhere to live longer, stronger, and with self-respect.

About Miskawaan Health Group

Miskawaan Health Group (MHG) combines cutting-edge German medical diagnostics with the wisdom of traditional holistic healing practices. The mission: to integrate the latest advancements in medical science with natural therapies to deliver personalised, patient-centred care.

About Jiuzhang Biotech

Jiuzhang Biotech is a pioneer in botanical medicine and natural product research. With more than 80 patents in proprietary extraction technologies, the company integrates traditional Chinese medicine with modern biotechnology to deliver pharmaceutical-grade raw materials and science-backed wellness solutions.

OROJIN™️ Makes Global Debut at BIOHK 2025 to Lead The Future of Preventive Medicine

Breakthrough Chewable Chlorogenic Acid Tablet Designed To Support Immunity, Cellular Vitality and Metabolism.


HONG KONG SAR – Media OutReach Newswire – 15 September 2025 – OROJIN™️, the breakthrough oral chewable tablet system was unveiled at BIOHK 2025, one of the world’s most influential biotechnology gatherings. Signalling the beginning of a new era in preventive medicine, OROJIN™️ was created to redefine the way people approach their health. More than a supplement, OROJIN™️ delivers a daily dose of chlorogenic acid, a powerful antioxidant that supports immunity, cellular vitality, and promotes metabolic harmony. A “Daily Act of Self-Respect”, OROJIN™️ empowers people everywhere to live stronger, healthier, and more fulfilled lives.

OROJIN™️ Makes Global Debut at BIOHK 2025 to Lead The Future of Preventive Medicine

Science That Protects

Developed in collaboration with leading professors and medical pioneers from the Miskawaan Health Group (MHG) and Jiuzhang Biotech, OROJIN™️ is built on advanced research into chlorogenic acid, one of nature’s most potent antioxidant compounds. Extracted from Eucommia leaves using a comprehensive, proprietary system, its researched benefits include:

  • Neutralizing free radicals that damage DNA and accelerate aging. 1
  • Calming chronic inflammation, the root cause of many diseases.2
  • Restoring healthy cell signalling and boosting natural energy transport in the body, leading to beneficial metabolic effects. 3
  • Protecting vital organs, including the heart, liver, gut, and brain. 4
  • Encouraging restful sleep, and supporting memory and focus. 5

A New Standard in Preventive Medicine

With OROJIN™️, science becomes simple, accessible, and actionable in everyday life. “OROJIN™️ is not just another product — it is the beginning of a movement,” said David Boehm, Chairman of OROJIN™️ and Miskawaan Health Group. “This launch represents a mindset shift, encouraging people to take a proactive interest and care in their own health and wellbeing journey. We are delighted to be part of a new and empowered approach to wellness that starts with daily proactive care,” he added.

Global Launch Celebration at BIOHK 2025

The launch celebrations were led by David Boehm, Chairman of OROJIN™️, and Miskawaan Health Group, and Zhang Jie, Founder and Chairman of Jiuzhang Biotech. They included a Ribbon Cutting Ceremony featuring the OROJIN PreventaPanda™️, a beloved symbol of proactive health.

References

  1. Ogawa H, et al. Chem Lett. 2023;52:524-527.
  2. Huang J, et al. Front Pharmacol. 2023 Sep 13:14:1218015.
  3. Meng S, et al. Evid Based Complement Alternat Med. 2013:2013:801457.
  4. Lu H, et al. Compr Rev Food Sci Food Saf. 2020;19:3130-3158.
  5. Saitou K, et al. Nutrients. 2018;10:1337.

Disclaimer: This product is not registered under the Pharmacy and Poisons Ordinance or the Chinese Medicine Ordinance. Any claim made for it has not been subject to evaluation for such registration. This product is not intended to diagnose, treat or prevent any disease.
Hashtag: #OROJIN

The issuer is solely responsible for the content of this announcement.

About OROJIN™️

is the world’s first complete preventive wellness system, built on decades of scientific research and inspired by the belief that prevention is the highest form of care. Designed for global impact, OROJIN™️ empowers individuals everywhere to live longer, stronger, and with self-respect.

About Miskawaan Health Group

Miskawaan Health Group (MHG) combines cutting-edge German medical diagnostics with the wisdom of traditional holistic healing practices. The mission: to integrate the latest advancements in medical science with natural therapies to deliver personalised, patient-centred care.

About Jiuzhang Biotech

Jiuzhang Biotech is a pioneer in botanical medicine and natural product research. With more than 80 patents in proprietary extraction technologies, the company integrates traditional Chinese medicine with modern biotechnology to deliver pharmaceutical-grade raw materials and science-backed wellness solutions.

Home Control (1747.HK) Announces Strategic Expansion into Healthcare Sector; Leveraging multi-disciplinary technologies which might include AIoT, Web3, expecting a potential increase in valuation

HONG KONG, Sept. 15, 2025 /PRNewswire/ — On 12 September, Home Control (1747.HK) announced a strategic expansion into the healthcare sector with plans to establish a wholly owned subsidiary in Hong Kong. The new entity will focus on incubating and integrating smart healthcare hardware, with the aim of building a people-centric health services ecosystem. Market observers expect the initiative to leverage multi-disciplinary technologies such as AIoT, Web3, digital assets and Real World Assets Tokenization (RWA), which could serve as catalysts for a potential re-rating of the Company’s valuation.

Platform Development Through Technology Integration

Home Control is prioritizing innovation by combining in-house R&D with integrated solutions designed for smart home healthcare settings. Its goal is to create a one-stop health management platform that aligns with global demands over the digital transformation of healthcare systems and secure data management. Research indicates that modernization of healthcare data and the establishment of resilient technology infrastructure require the application of cloud computing, generative AI and related emerging technologies. The convergence of AIoT, Web3 and RWA with healthcare is widely viewed as a natural extension of the Company’s strategy.

To support these ambitions, Home Control has strengthened its Board. Newly appointed Independent Non-Executive Director Mr. Ye Min previously served as Managing Director and Head of International Business at Moody’s, and as Chief Executive Officer of China Chengxin International (CCXI), the country’s first nationwide credit rating agency. With deep expertise in Web3 finance, risk management and ESG, Mr. Ye is expected to provide strategic and compliance insights as the Company advances into healthcare.

Strategic resources in the Asian healthcare market

Another new Independent Non-Executive Director, Mr. Chen Yi Chung, adds significant regional healthcare experience. Through OUE Group, a Singapore-listed healthcare and property group, he has overseen investments and operations across Asia. OUE’s healthcare subsidiary, Healthway, runs over 130 clinics and medical centers in Singapore, with an expanding footprint in China, Myanmar, Indonesia and Japan. Key milestones include the operation of a hospital in Myanmar (2019), the establishment of an international medical centre in Shenzhen in partnership with the Chinese University of Hong Kong (2023), and the acquisition of a leading Singapore physiotherapy provider (2024). Mr. Chen’s expertise and network are expected to be highly complementary to Home Control’s healthcare ambitions.

Bridging Gaps in the Global Healthcare Ecosystem with Extensive Resources

Healthcare data is growing rapidly — at an estimated CAGR of 36% from 2020 to 2025 — yet infrastructure and integration remain underdeveloped. These barriers have discouraged many private enterprises from entering the sector. By proposing the creation of a global healthcare services ecosystem, Home Control is aiming to address these gaps by bridging data flows between households and clinics and exploring new healthcare delivery models.

The Company’s vision is to create a people-focused healthcare network that connects device makers, healthcare service providers, insurers and other stakeholders. Such integration requires advanced technology, strong relationships and deep market insight. Market commentators note that Home Control’s increasingly proactive communication of its strategy signals the depth of resources backing its ambitions.

Earlier this year, the Company appointed Ms. Ma Ying as a Non-Executive Director. Ms. Ma co-founded the Zhejiang Jack Ma Public Welfare Foundation in 2014 and served as its Chairman and Legal Representative. Her profile in philanthropy and education, along with her ties to leading figures in China’s new economy, have fuelled market expectations that she could play a supportive role in Home Control’s future healthcare expansion.

Global Healthcare at a Digital Inflection Point, showcasing tremendous opportunities

Industry consensus suggests that global healthcare systems are at a tipping point where digitalization is no longer optional but urgent. Deloitte’s 2025 Global Healthcare Outlook highlights that leaders in markets such as the US, UK, Germany, Canada, the Netherlands and Australia are prioritizing digital transformation and investing heavily in healthcare as a high-growth sector. Against this backdrop, Home Control’s entry into healthcare — supported by new Board members with expertise in Web3, finance and medical services — positions the Company to capture a meaningful share of this emerging growth opportunity.

Luang Prabang to Celebrate That Chomsi Stupa Ceremony This October

Chonsi Stupa in Luang Prabang Province (Photo: Encircle) Photos

Luang Prabang is set to host the That Chomsi Stupa ceremony from 5 to 6 October, celebrating the city’s cultural traditions and the stupa’s spiritual significance. 

BCI Shines at the RE+2025 Energy Expo in Las Vegas

LAS VEGAS, Sept. 15, 2025  /PRNewswire/ — BCI, an Indonesian solar cell manufacturer, achieved remarkable success at the 2025 RE+ Expo held in Las Vegas from September 8-11. As North America’s largest clean energy platform, RE+ brought together global industry leaders, where BCI (PT.BINTAN CELLULAR INDONESIA) BCI demonstrated its technological prowess in solar cells and established valuable partnerships.


The BCI booth was always crowded with visitors. BCI comprehensively displayed its product lines covering high-efficiency cells and next-generation ultra-high-efficiency technologies. Its full range of photovoltaic cells have won wide acclaim from the professional audience with their ultra-high conversion efficiency, ultra-low energy consumption design and excellent temperature coefficient performance. It is worth noting that the core products have passed a number of international authoritative tests and comply with the compliance guidelines of the North American market, providing local customers with a reliable option for quick landing.

The event generated overwhelming industry interest in BCI. Numerous potential clients engaged in in-depth discussions, expressing strong cooperation intentions. This enthusiastic response validates BCI’s technological strengths and market competitiveness in the global renewable energy sector.

BCI remains committed to driving the clean energy transition through continuous innovation. Leveraging our manufacturing base in Indonesia, we are actively strengthening the connection between Southeast Asian production capacity and the North American market. Moving forward, BCI will collaborate with global photovoltaic partners to contribute to a sustainable energy future worldwide.